Effects of hepato-preferential basal insulin peglispro on nuclear magnetic resonance biomarkers lipoprotein insulin resistance index and GlycA in patients with diabetes.

Abstract

AIM:

To characterize the effects of hepato-preferential basal insulin peglispro (BIL) and insulin glargine on insulin resistance (lipoprotein insulin resistance index [LP-IR]) and inflammation (GlycA), and to explore the biological implications.

METHODS:

This substudy included 847 patients with Type 1 diabetes (T1D) or Type 2 diabetes (T2D) in four cohorts of the BIL development program. LP-IR and GlycA were measured before and after insulin treatment. Correlations between LP-IR, GlycA, clinical parameters and liver biomarkers were assessed.

RESULTS:

LP-IR and GlycA were higher in T2D than T1D. LP-IR increased in patients switched from basal insulins to BIL but not in insulin-naive patients. GlycA decreased in T2D patients treated with BIL and T1D patients treated with glargine.

CONCLUSION:

These exploratory analyses help to characterize differences in biological effects between BIL and glargine treatment.

• Authors: Margery A Connelly, James D Otvos, Qianyi Zhang, Shuyu Zhang, Caryl J Antalis, Annette M Chang, Byron J Hoogwerf
• Journal: Biomarkers in medicine (Biomark Med) Vol. 11 Issue 11 Pg. 991-1001 (Nov 2017) ISSN: 1752-0371 [Electronic] England
• PMID: 29160108 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study)

Chemical References

• Biomarkers
• Lipoproteins
• Insulin Glargine

Topics

• Aged
• Biomarkers (blood)
• Diabetes Mellitus, Type 1 (blood, drug therapy)
• Diabetes Mellitus, Type 2 (blood, drug therapy)
• Female
• Humans
• Insulin Glargine (administration & dosage)
• Insulin Resistance
• Lipoproteins (blood)
• Male
• Middle Aged